Peregrine Pharmaceuticals Inc., of Tustin, Calif., said a previously approved 1-for-7 reverse split of its outstanding shares of common stock took effect Friday, July 7, and will begin trading on Nasdaq Monday, July 10, on a split-adjusted basis under the existing trading symbol PPHM. Read More
Alk-Abello A/S, of Horsholm, Denmark, released further analysis of data from its landmark five-year Grazax asthma prevention (GAP) trial in children. The analysis, which appears online in The Journal of Allergy and Clinical Immunology, shows that the benefits of Grazax in prevention of asthma symptoms were even more pronounced when treatment was initiated at an earlier age. Read More
By screening for glioblastoma targets in vivo using mouse models with patient-derived xenografts, researchers have identified new potential targets for drugs to treat glioblastoma. Read More
Zealand Pharma A/S, of Glostrup, Denmark, filed with the SEC to raise up to $86 million in a U.S. IPO. The number of American depositary shares and share price have not yet been disclosed. Read More
Emmaus Medical Inc.'s pharmaceutical-grade L-glutamine cleared the FDA on its July 7 PDUFA date, becoming the first new treatment for sickle cell disease (SCD) in the U.S. since chemotherapeutic agent hydroxyurea gained approval in 1998, and the first treatment indicated for pediatric patients. Read More
An international research collaboration has found a means to improve the effect of mimetics of the second mitochondrial-derived activator of caspase (Smac), a novel class of targeted cancer drugs that act by inducing apoptotic cancer cell death and inhibiting pro-survival signaling. Read More
An antithrombin-targeting RNAi therapy for hemophilia, fitusiran, developed by Alnylam Pharmaceuticals Inc. with Sanofi Genzyme, is entering phase III territory. The three-part Atlas trial program, in hemophilia A and B, is expected to yield top-line data in mid to late 2019. Its start, just days before results of an ongoing phase II study are scheduled to be detailed at a Berlin medical meeting, triggers a $25 million milestone payment for Alnylam and marks the kick-off of the last leg in a race to approval with Roche Holding AG's bispecific monoclonal antibody emicizumab. Read More
In previous antibiotic drug development, "you would always look for the one molecule and the one dose that you could use for everything," Entasis Therapeutics Inc. CEO Manos Perros told BioWorld. "Maybe that approach has reached its limit." Read More
The sun has been shining on the biopharmaceutical sector of late as investors have returned to the sector big time. As a result, the BioWorld Biopharmaceutical index grew a healthy 6.6 percent in the second quarter, well ahead of the general markets, thanks to a late June spurt in valuations, causing the index to grow 5.8 percent last month. Read More